Human Co., Ltd. Skin Clinical Trial Center

Human Skin Clinical Trials Center

Clinical Trial Report



International Industry

Test Product

Goume Sleeping Mask Pack

Study Code

HM-IR0073-43

Report Date

2025-11-19

HUMAN
Human Co., Ltd.
Skin Clinical Trial Center

1005~1008, 24, Gasan digital 1-ro, Geumcheon-gu, Seoul, Republic of Korea
Tel. 070-5222-9663 (extension 1 for test consultation)
Fax. 070-7500-9650
E-mail. skin@humantest.co.kr

TEST REPORT CERTIFICATION

Certification Code: HM-IR0073-43

Client: International Industry

Representative: Park Chan woo

Address: KR Law Tower, 6, Ieum 4-ro, Seo-gu, Incheon

Test Result			
Test Item	**Product**	**Result**	**Irritation Evaluation**
Primary skin irritation test	Goume Sleeping Mask Pack	0.00	No irritation (Excellent)
Test Methods: After wiping the subject's test area with 70% ethanol and drying it, the test product was loaded into a Finn Chamber® and attach it on the skin for 24 hours. The dermatologist assessed whether skin irritation was present at 30 minutes and 24 hours after patch removal.			

Skin Irritation Index	Irritation Evaluation
0.00 ~ 0.25	No irritation (Excellent)
0.26 ~ 1.00	Mild irritation (Good)
1.01 ~ 2.50	Medium irritation (Bad)
2.51 ~ 4.00	Strong irritation (Very Bad)

Authentication

Goume Sleeping Mask Pack	
Study item	Primary skin irritation test

This study requested by International Industry was conducted in accordance with the GCP (Good Clinical Practice), guidelines of MFDS (Ministry of Food and Drug Safety) and the Standard operation procedure of Human Co., Ltd. Skin Clinical Trial Center. The results are reported as follows.

2025-11-19

President	Human Co., Ltd. Skin Clinical Trial Center	Huijeong Jeong
Principal Investigator	Human Co., Ltd. Skin Clinical Trial Center	Wonkyu Hong, M.D., Ph.D.

Contents

TEST REPORT CERTIFICATION **1**
Contents **3**
Information of the Study Request **5**
Quality Assurance Statement **6**
Report Summary **8**
1. Study purpose 9
2. Investigational product and Ingredients 9
3. Subjects 10
3.1. Inclusion criteria 10
3.2. Exclusion criteria 10
3.3. Number of subjects 10
3.4. Criteria for premature withdrawal and dropout from the study 11
3.5. Regulations on Human Application Tests for Test Subjects 11
3.6. Subject Obligations 12
3.7. Confidentiality of Information and Fiduciary Duty 12
4. Methodology 13
4.1. Materials to conduct the study 13
4.2. Test method and test site 13
4.3. Evaluation procedure 13
4.4. Determination of irritation 14
4.5. Evaluation of skin adverse event 14
5. Results 15
5.1. Results of skin primary irritation test 15
5.2. Evaluation result of skin adverse event 15
6. Conclusion 16
7. References 17
8. Appendix 18
Appendix 1. Subject Test Guideline Document and Compensation Policy for Participants 18

Appendix 2. Subjects' information 22
Appendix 3. Data of patch test result 23
Institutional Assessment Report 24
Research Resume 25
List of publications 29

Information of the Study Request

Study Title	Primary skin irritation test of [Goume Sleeping Mask Pack]	
Study Code	HM-IR0073-43	
IRB Code	HM-IRB-IR0073-43	
Clinical Trial Center	**Test Center**	Human Co., Ltd. Skin Clinical Trial Center
	Address	1516~1517ho, 62, Digital 31-gil, Guro-gu, Seoul, Republic of Korea
	President	Huijeong Jeong
	Principal Investigator	Wonkyu Hong / Dermatologist
	Investigator	Dahyeon Kim / Chief Researcher
	Tel.	+82-2-6741-0376
	E-mail	kdh@humantest.co.kr
Sponsor	**Name**	International Industry
	Address	KR Law Tower, 6, Ieum 4-ro, Seo-gu, Incheon
	President	Park Chan woo
	Monitor	Jung Hyo min
	Tel.	+82-10-9978-2182
	E-mail	soul_adm@naver.com

Quality Assurance Statement

Study Title	Primary skin irritation test of [Goume Sleeping Mask Pack]
Study Code	HM-IR0073-43
IRB Code	HM-IRB-IR0073-43
Study Period	2025-11-04 ~ 2025-11-06

A Clinical trial study for humans was conducted accurately in accordance with the test protocol agreed upon with International Industry, GCP (Good Clinical Practice), MFDS (Ministry of Food and Drug Safety) guidelines, and the Standard Operating Procedures (SOP) of Human Co., Ltd. Skin Clinical Trial Center. We confirm that the results have been faithfully reflected. All result obtained during the study period have been faithfully reflected in this report, and it is certified that all procedures of this clinical trial were inspected under the supervision of quality assurance and received finally approval from principal investigator, as detailed below.

Classification	Inspection Items	Inspection Date	Status of Approval
Equipment and Facilities	Routine Inspection of Equipment	2025-10-30	Approval
	Document and Sample Storage Facility		Approval
	Laboratory Structure		Approval
Study Plan	Study Protocol	2025-10-29	Approval
	IRB Approval	2025-10-30	Approval
	Preparation of Test Product Information	2025-11-03	Approval
	Subject Recruitment		Approval
Study Process	Study Procedure and Data Analysis	2025-11-04 ~ 2025-11-06	Approval
	IRB Study Completion Certification	2025-11-18	Approval
Report	Finial Reported Date	2025-11-19	Approval
	Documents Storage	2025-11-19	Approval

2025-11-19

Principal Investigator: Wonkyu Hong

Quality Assurance: Hongsuk Kim

Report Summary

<table>
<tr><td>Study Title</td><td colspan="3">Primary skin irritation test of [Goume Sleeping Mask Pack]</td></tr>
<tr><td>Clinical Trial Center</td><td>Human Co., Ltd. Skin Clinical Trial Center</td><td>Sponsor</td><td>International Industry</td></tr>
<tr><td>Study Code</td><td>HM-IR0073-43</td><td>IRB Code</td><td>HM-IRB-IR0073-43</td></tr>
<tr><td>Study Period</td><td colspan="3">2025-11-04 ~ 2025-11-06</td></tr>
<tr><td>Purpose</td><td colspan="3">To evaluate the safety in terms of primary skin irritation on humans of [Goume Sleeping Mask Pack].</td></tr>
<tr><td>Results</td><td colspan="3">1. Subjects
Final Number of Subject (Average age): 33 (58.88yrs)

2. Results
<table><tr><th>Skin Irritation Index</th><th>Concentration*</th><th>Irritation Evaluation</th></tr><tr><td>0.00</td><td>As is</td><td>No irritation (Excellent)</td></tr><tr><td colspan="3">* Applied to 1% concentration with distilled water, in case of the product such as "Wash-off type"</td></tr></table>
3. There were no reports of any specific adverse skin reactions during the period when the test subjects used the test product, and no abnormal findings were observed in the physical examination by the dermatologist.</td></tr>
<tr><td>Conclusion</td><td colspan="3">[Goume Sleeping Mask Pack] requested by International Industry was considered a No irritation (Excellent) product in terms of primary skin irritation test.</td></tr>
</table>

1. Study purpose

Primary irritation human application test using a skin patch was performed to evaluate the safety of the [Goume Sleeping Mask Pack] requested by International Industry by measuring the irritation index on the human skin.

2. Investigational product and Ingredients

Table 1. Test Sample All Ingredients

No.	Identification code	Name	Formulation
E-3	251104-IR-43	Goume Sleeping Mask Pack	Sleeping Pack
Water, Glycerin, Propanediol, Pentylene Glycol, Niacinamide, 1,2-Hexanediol, Squalane, Butylene Glycol, Betaine, Ammonium Acryloyldimethyltaurate/VP Copolymer, Polyglyceryl-10 Laurate, Carbomer, Fragrance, Tromethamine, Macadamia Ternifolia Seed Oil, Cetyl Ethylhexanoate, Butyrospermum Parkii (Shea) Butter, Allantoin, Ethylhexylglycerin, Tocopherol, Panthenol, Hydrogenated Polydecene, Polyglyceryl-2 Stearate, Glyceryl Stearate, Stearyl Alcohol, Caprylic/Capric Triglyceride, Polyglyceryl-3 Methylglucose Distearate, Adenosine, Dextrin, Disodium EDTA, Hexamethylindanopyran, Hexyl Cinnamal, Hydroxycitronellal, Gardenia Florida Fruit Extract, Gelatin, Linalool, Geraniol, Sodium Hyaluronate, Citronellol, Glutathione, Acacia Senegal Gum, Eclipta Prostrata Extract, Cellulose Gum, Glycine, Serine, Glutamic Acid, Hydroxypropyltrimonium Hyaluronate, Melia Azadirachta Leaf Extract, Aspartic Acid, Leucine, Alanine, Lysine, Arginine, Tyrosine, Phenylalanine, Valine, Threonine, Proline, Isoleucine, Histidine, Moringa Oleifera Seed Oil, Methionine, Cysteine, Sodium Acetylated Hyaluronate, Hydrolyzed Hyaluronic Acid, Hyaluronic Acid, Sodium Hyaluronate Crosspolymer, Hydrolyzed Sodium Hyaluronate, Potassium Hyaluronate		

3. Subjects

3.1. Inclusion criteria

- Male and female adults over the age 20 years old
- Subjects who signed consent form voluntarily after being sufficiently informed regarding the objectives of study and all related contents
- Subjects who are healthy without acute and chronic diseases including skin disorders
- Subjects who can be observed and traced throughout the entire study period

3.2. Exclusion criteria

- Subjects who is pregnant or breast-feeding
- Subject who has psychiatric disease and infectious skin disease
- Subject who has skin lesion on the test site such as moles, pimples, erythema, scalds (burns), hemotelangiosis, and scars
- Subject who has atopic skin disease
- Subject who has used skin ointment containing steroid on the test site for more than one month
- Subjects who have sensitive and hypersensitive skin
- Subject who has irritation history or allergy to adhesive tape
- Subject who has been part of the same clinical trial within the past 3 months
- Subject who is on contraceptive, anti-histamine and anti-inflammatory prescriptions
- Subject who has cosmetics or sunlight allergies
- Employee in this clinical trial center
- Anyone who is considered non-qualified by the investigator

3.3. Number of subjects

This study was conducted in compliance with the "Regulations on Functional Cosmetic Examination [Annex 1] Toxicity Test Method Section 7 (1) Human patch test method" by the MFDS (Ministry of Food and Drug Safety).

The results were calculated by obtaining the valid data from a minimum of 30 subjects.

3.4. Criteria for premature withdrawal and dropout from the study

The subjects who participating in this study can withdraw from the clinical trial any time, and the investigator can eliminate subjects from this test and exclude the data on the subject from the test result evaluation in the event of occurrence of one or more of the following reasons. When a subject is withdrawn, the investigator shall specify the corresponding reason and records other relevant matters to report to the principal investigator.

(1) Voluntary withdrawal by the subject
(2) Violation of the protocol
(3) Occurrence of adverse event or seriously adverse event on the test site of a subject
(4) Failure to follow up on the subject
(5) Others

3.5. Regulations on Human Application Tests for Test Subjects

This human application test was carried out in accordance with the spirit of the Declaration of Helsinki and the GCP Guidelines to protect the rights, safety, and welfare of test subjects in the first place. The investigator faithfully implemented the following to ensure the safety of the test subjects.

(1) During the test, the principal investigator and the examiner shall do their best to ensure the safety of the test subjects, and in the event of an adverse reaction, take prompt and appropriate measures to minimize the reaction.
(2) If a test subject reports skin irritation or adverse reaction due to the test product during the trial, wipe off the used test product immediately, and if the symptoms do not improve, receive dermatological evaluation and appropriate treatment by the principal investigator.
(3) If an adverse reaction occurs despite the normal course of the test, appropriate dermatological evaluation and treatment should be conducted.
(4) In the event of any other abnormal skin reactions, the principal investigator and the investigator shall take appropriate measures along with the dermatological evaluation, and record the case and situation in detail.

3.6. Subject Obligations

- Comply with all inspection schedules during the trial period.
- Ensure that all symptoms that occur during the trial period are reported in detail and thoroughly.
- During this examination period, all materials such as questions and questionnaires of the examiner must be filled out sincerely and honestly.

3.7. Confidentiality of Information and Fiduciary Duty

- The confidentiality of the test subjects participating in this trial will be guaranteed. However, test data may be used for medical, academic research, or marketing purposes to the extent that the subject's identity is not revealed.
- Subjects must keep confidential information obtained through this test until the end of the trial.
- Subjects participating in this test must fill out the data with sincerity and honesty.

4. Methodology

This study was conducted in a temperature and humidity controlled area (indoor temperature 22±2℃, humidity 50±5%) within the HUMAN Co., Ltd. Skin Clinical Trial Center.

4.1. Materials to conduct the study

1) Finn Chamber® on Scanpor® (SmartPractice®, U.S.A.)
2) Microman M100 (Gilson, France)
3) Micropore tape (3M/ Medical-Surgical Division)
4) Marking pen (Skin marker Slim, Sweden)

4.2. Test method and test site

Test site was located on the subject's back, avoiding the spine area and any area with skin discoloration or any lesion. 20μl of test products were applied on the patch chamber and patches were fixed to the test area for 24 hours. The skin reaction was assessed 30 minutes and 24 hours after the patch was removed.

4.3. Evaluation procedure

Table 2. Evaluation procedure

Actions	Day 1	Day 2	Day 3
Admission of the subjects by the investigator	√	-	-
Application of the investigational product and giving the subjects constrains of the study	√	-	-
Remove the patch	-	√	-
Observation of test site after 30 min of the patch removal	-	√	-
Observation of test site after 24 hrs of the patch removal	-	-	√

4.4. Determination of irritation

The index of skin irritation was calculated based on guidelines proposed by Frosch & Kligman and CTFA guidelines (2007), and then the degree of skin irritation of the test product was evaluated using the skin irritation index of the Draize method (Table 3, 4, Fig 1).

Table 3. Skin Irritation Evaluation Criteria

Mark	Grade	Description
-	0	No reaction
+	1	Slight erythema, either spotty or diffuse
++	2	Moderate uniform erythema
+++	3	Intense erythema with edema
++++	4	Intense erythema with edema & vesicles

Fig 1. Skin Irritation Index Formula

$$\text{Skin Irritation Index} = \frac{\left[\left(\frac{\sum_{i=1}^{n} Evaluation\ Value}{n(Number\ of\ Test\ Subjects)}\right)30min + \left(\frac{\sum_{i=1}^{n} Evaluation\ Value}{n(Number\ of\ Test\ Subjects)}\right)24hrs\right]}{m(Number\ of\ times\ evaluated)}$$

Table 4. Result Determination Table of Skin Patch Test

Primary Irritation Index	Irritation Evaluation
0.00 ~ 0.25	No irritation (Excellent)
0.26 ~ 1.00	Mild irritation (Good)
1.01 ~ 2.50	Medium irritation (Bad)
2.51 ~ 4.00	Strong irritation (Very Bad)

4.5. Evaluation of skin adverse event

The researchers monitored for any adverse skin reactions during the test period and reviewed the use of concomitant medications that could possibly affect the test. In the event of a negative reaction, the researchers will promptly inform the study director who will then take necessary measures and determine whether to proceed with involvement after verification.

5. Results

5.1. Results of skin primary irritation test

Dermatologist conducted a visual evaluation 30 minutes and 24 hours after removing the patch. As a result, the investigational product [Goume Sleeping Mask Pack] was classified as No irritation (Excellent) range for human skin primary irritation.

5.2. Evaluation result of skin adverse event

No adverse reactions or observed concomitant medication use were reported or observed during the study period.

6. Conclusion

Primary irritation human application test using a skin patch was performed to evaluate the safety of the [Goume Sleeping Mask Pack] requested by measuring the irritation index on the human skin.

1. Subjects

   Final Number of Subject (Average age): 33 (58.88yrs)
2. Test Results

   This test product showed a skin irritation index of 0.00, No irritation (Excellent).
3. There were no reports of any specific adverse skin reactions during the period when the test subjects used the test product, and no abnormal findings were observed in the physical examination by the dermatologist.

[Goume Sleeping Mask Pack] requested by International Industry was considered a No irritation (Excellent) product in terms of primary skin irritation test.

7. References

1) Guidelines for test methods for demonstrating cosmetic mark advertising, Ministry of Food and Drug Safety. 2014.

2) Guidelines for cosmetic clinical and efficacy examination, Ministry of Food and Drug Safety. 2012.

3) Basketter DA, Chamnerlain M, Griffiths HA, Rowson M, Whittle E, York M. The classification of skin irritants by human patch test. Food Chem Toxicol. 1997:37(8): 845-52.

4) CTFA Safety Testing Guideline: The Cosmetic, Toiletry and Fragrance Association, Inc. Washington, D.C. 1981:20005.

5) CTFA Safety Testing Guideline: The Cosmetic, Toiletry and Fragrance Association, Inc. Washington, D.C. 1991:20036.

6) Devos SA, Van Der Valk PG. Epicutaneous patch testing. Eur J Dermatol. 2002:12(5): 506-13.

7) Draize J.H., Woodard G., Calvery H.O. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J. Pharm. Exp. Ther. 1994:82:377-390.

8) Draize J.H. Dermal Toxicity Appraisal of the Safety of Chemicals in Foods, Drugs and Cosmetics, Association of Food and Drug Officials of the United States, Austin, Tex, USA. 1959.

9) Electrical impedance applied to non-invasive detection of irritation in skin. Contact dermatitis. 1992:27:37-42.

10) Fischer T, Maibach H. Finn chamber patch test technique. Contact dermatitis. 1984: 11(3):137-140.

11) Frosch P. J. & Kligman A.M. The soap chamber; a new method for assessing the irritancy. J. Invest. Dermtol. 1979:40:11-14.

8. Appendix

Appendix 1. Subject Test Guideline Document and Compensation Policy for Participants

A manual for the consent of the subject

Primary skin irritation test on '80 Test samples'

The decision to participate in this study is up to you, and everything is up to you to decide to participate or give up according to your free will. The information below is information on this human application test and is designed to explain the contents of this human application test and your role and research process if you participate in this study. After you have enough time to review and read it, you can consult with your family or others. If you have any questions, please contact the research manager or test manager and decide whether to participate in the test.

1. Purpose and Method of Human Application Test

Human Co., Ltd. Skin Clinical Trial Center would like to conduct a human application test of 80 Test samples.

1) This test aims to check the primary irritation caused by skin adhesion for adult men and women over the age of 20.

2) The test product is used in the back, and the primary stimulation of the product is evaluated before and after use.

3) A total of more than 30 subjects participate in the test, and they visit three times in three days, and each visit takes about 30 to 60 minutes.

2. Information on test products

The test product is cosmetics, which are removed after 24 hours of patch.

3. What you need to comply with

This matter must be observed for the purpose of protecting the subject and ensuring accurate research.

1) Please keep the schedule for use and inspection of the human body application test products.
2) While using the test product, please report it in detail to the research director or test person before using the drug or other product.
3) If you experience any adverse reactions while using the test product, please contact the research manager or test manager immediately and follow the instructions. If you need to undergo further testing, you should visit the Human Dermatology Department or the main center for testing.
4) Prohibits the use of products or medicines that may exhibit the same or similar effect as test products during testing.
5) Please avoid excessive UV exposure, skin care, massage, plastic surgery, vacation to other climatic areas, and stress while using test products.
6) The information obtained through this test must be kept confidential until the end of the test.

4. Adverse reactions or side effects predicted by participation in the human body application test

While participating in this test and using cosmetics, irritable skin may have unexpected risks such as stinging, rash, irritation, erythema, human face, swelling, etc. Therefore, when information on safety and side effects is collected during the human body application test, we will provide the information to the subject or legal representative in a timely manner.

5. Restrictions on Participation in Human Application Examinations

In this test, the case of pregnant women, or pregnant women who do not have an appropriate contraceptive plan or pregnant women who do not do appropriate contraception test methods.

6. Matters provided when participating in human application test

By participating in this examination and inconvenience products generated by participating in this examination, and inconvenience for time loss and inconvenience incurred due to the test participation. However, if you voluntarily withdraw the planned test or visit the planned test, separate transportation fee will not be paid to test before the test participation.

7. An expected profit

There are no expected therapeutic benefits even if you participate in this clinical trial.

8. Compensation, indemnity, or treatment in the event of injury related to the human application test

Among this test period, researchers will try best to protect your safety and minimize response to your safety when a significant reaction occurs and appropriate measures. If damage occurs in relation to human application test, Andaba company will compensate in accordance with this center, will be compensated in accordance with this center.

9. Withdrawal after consent to participate in the human body application test

This test is voluntary participation by yourself, and you can always withdraw participation if you wish to discontinue it. If you wish to withdraw participation, please contact our examiners at this center.

10. A secret security guarantee

All records of your personal information obtained during the course of this exam will be confidential. As a result of this examination, your personal information will remain confidential even if the photographs and related data are published for the purpose of thesis and advertising. In addition, all records related to this examination will be preserved for three years from the end of this study.

11. Collecting and utilizing personal information

Your personal information (name, phone number, address, date of birth, gender, test information) will be used for the purpose of identifying the subject and conducting this test. The collected personal information, along with the test-related documents, will be stored in a place where access is restricted in accordance with the test-related laws and internal regulations of the test laboratory, and discarded. You have the right to refuse consent to collect and use personal information and to provide it to a third party, and if you do not consent, you cannot participate in the test.

12. Sign

Once you have answered all the questions you are curious about and have decided that you would like to participate in this test, you can sign a separate consent form for participation in the Human Application Test.

13. Contact Information

If you have any further information about this exam, any damage related to the exam, or need contact, you may have a telephone interview or consultation with the following research officers and examiners.

Sortation	Name	Tel.
Research director	Wonkyu Hong	+82-10-9651-3555
Investigator	Dahyeon Kim	+82-6741-0376

Appendix 2. Subjects' information

No.	Initial	Age	Gender
01	KCG	71	F
02	YSH	60	F
03	MKH	55	F
04	KHH	61	F
05	PJH	63	F
06	ISY	63	F
07	ASY	51	F
08	ISJ	64	M
09	SJS	53	M
10	IDH	57	F
11	KJM	59	F
12	KHJ	41	F
13	KYJ	51	M
14	IHJ	63	F
15	KYG	68	F
16	KEH	65	F
17	KMS(E)	60	F
18	IMR	62	F
19	NJY	51	F
20	OHY	62	F
21	HSY	53	F
22	BMY	48	F
23	JKS	60	F
24	KMO	54	F
25	PJM	60	F
26	KMJ	63	F
27	PSH	64	F
28	BJH	62	F
29	PMG	50	F
30	IKN	65	F
31	KYS	63	F
32	CYJ	55	F
33	JYO	66	F

Appendix 3. Data of patch test result

No.	30min	24hrs
01	0	0
02	0	0
03	0	0
04	0	0
05	0	0
06	0	0
07	0	0
08	0	0
09	0	0
10	0	0
11	0	0
12	0	0
13	0	0
14	0	0
15	0	0
16	0	0
17	0	0
18	0	0
19	0	0
20	0	0
21	0	0
22	0	0
23	0	0
24	0	0
25	0	0
26	0	0
27	0	0
28	0	0
29	0	0
30	0	0
31	0	0
32	0	0
33	0	0

**0-No reaction, 1-Slight erythema, either spotty or diffuse, 2-Moderate uniform erythema, 3-Intense erythema with edema, 4-Intense erythema with edema & vesicles*

Institutional Assessment Report

■ Clinical Trials Information			
Name	Human Co., Ltd. Skin Clinical Trial Center		
Address	1005~1008, 24, Gasan digital 1-ro, Geumcheon-gu, Seoul, Republic of Korea		
President	Heejung Jung		
Principal Investigator	Wonkyu Hong / Dermatologist		
Phone Number	070-5222-9663	**Fax**	070-7500-9650
E-mail	skin@humantest.co.kr		

■ Objectives of the Clinical Trials Center
This institution was established to perform human clinical studies on skin products to assess their safety, efficacy, and functionality. It also provides the results of these studies and relevant technical information

■ Clinical Trials Items	
Cosmetic Safety Evaluation and Research	Evaluation and Research of functional Cosmetic
Cosmetic Efficacy Evaluation and Research	Evaluation and Research of Quasi-Drugs
Evaluation and Research of Skin-related products	Evaluation and Research of Functional Foods

■ Facility		
A thermo-hygrostat	VECTRA XT	Mark-Vu
F-ray	DSLR (Cannon EOS 80D)	Antera 3D
DUB® SkinScanner	Epsilon E100	Electronic scale
Cutometer® dual MPA 580	Corneometer® CM825	Sebumeter® SM815
Tewameter TM300	VISIA-7	PRIMOS CR
Moisturemeter D	Vapometer	SkinGlossMeter
SkinColorCatch	Skin pH meter	FLIR E75
Kong Camera	Dino-Lite Digital Microscope	Folliscope 5.0
Fine dust injection system	Infrared Moisture Analyzer	Bathtub
Infrared Sauna System	IR lamp	Black D-Squame
Static meters	Ballistometer BLS780	Clean bench
Incubator	Auto clave	Water Purification System
DERMAVISION Beauty Edition	MulteTest-dV	3D Meta-Vu
UV-PCL 1000	EM-30P	-

Research Resume

■ **President**

Heejung Jung / CEO

Education	2004	Graduated from Department of Environmental Engineering, Konkuk University, bachelor of engineering
Career	2018 ~ 2020	Head of Skin Clinical Trial Center, OATC Co., Ltd.
	2020 ~ present	CEO of Human Skin Clinical Trial Center

Reliability review of whitening function evaluation using transparent film mapping

Blue light blocking test device patent registration[10-2346709]

Patent registration of anti-dust performance test device and method[10-2019883]

Patent application for portable cosmetic container[10-2019-0052712]

Patent application for cosmetics sterilizer[10-2019-0080854]

Patent application for cosmetic container with temperature control[10-2019-0084935]

Patent application for skin heavy metal measuring device[10-2019-0168852]

Cereal skin type analysis and patent application for customized cosmetics manufacturing device[10-2020-0068940]

■ **Principal Investigator**

Wonkyu Hong / Dermatologist

Education	2004	Graduated from Inha University School of Medicine, Bachelor of Medicine
	2004 ~ 2005	Intern of Inha University Hospital
	2005 ~ 2009	Resident of Inha University Hospital
	2007	Graduated from Inha University School of Medicine, Master of Medicine
Career	2004	Acquired Doctor's License (License number: 83931)
	2009	Acquired dermatologist (License number: 1771)
	2009 ~ 2012	Associate Chairman of Hansen Welfare Association Jeonbuk Branch
	2013 ~ 2015	Representative Director of Pyeongtaek Human Dermatology
	2013 ~ present	Adjunct Professor of Dermatology Class, Inha University
	2016	Representative Director of Cheongna Human Dermatology
	2018	Research Director of Human Cosmetic
	2018	Adjunct Professor of International St. Mary's Hospital
	2018 ~ 2020	Research Director of Skin Clinical Trial Center, OATC Co., Ltd.
	2020 ~ present	Research Director of Human Skin Clinical Trial Center
Society activities		Regular member of Korean Society of Dermatology
		Regular member of the Korean Society for Acne Research
		Regular member of Korean Hair Research Society
		Regular member of Association of Korean Dermatologists
	2018 ~ present	Intelligence member of Association of Korean Dermatologists
	2018 ~ present	Planning policy member of Association of Korean Dermatologists

■ **Quality Assurance**

Hongsuk Kim / Dermatologist

Education	2001	Graduated from Dong-A University College of Medicine, Bachelor of Medicine
	2001 ~ 2002	Intern of Dong-A University Hospital
	2002 ~ 2006	Resident of Dong-A University Hospital
	2004	Master of Dermatology, Dong-A University College of Medicine, Master of Medicine
Career	2001	Acquired Doctor's License(License number: 72561)
	2006	Acquired dermatologist (License number: 1629)
	2006 ~ 2009	Manager, Jeju Special Self-Governing Province Branch, Korea Hansen Welfare Association
	2010 ~ 2011	Manager of Nohyung Beautiful Dermatology
	2011 ~ 2012	Representative Manager of Dermatology, Seoul Clinic
	2014 ~ present	Adjunct Professor of Dermatology Class, Dong-A University,
	2012 ~ present	Representative director of Wine Dermatology Plastic Surgery
	2015 ~ present	Clinical Instructor of Department of Medical Beauty, Chungcheong University
	2016 ~ present	Clinical Instructor of Cosmetics Consulting Professional Association
	2020 ~ present	Human Skin Clinical Trial Center Reliability assurance officer
Society activities		Publication director of the Korean Society for Anti-aging Dermatology
		Director of the Korean Society for Skin Type Research
		Director of the Korean Society of Cosmetics and Cosmetology
		Regular member of Korean Society of Dermatology
		Regular member of Korean Society of Dermatology Surgery
		Regular member of Korean Medical Society for Cosmetics
		Regular member of Korean Laser Society
		Regular member of the Korean Society for Psoriasis
		Regular member of the Korean Society for Acne Research
		Regular member of Korean Society of Vitiligo
		Regular member of the Korean Atopic Dermatitis Association

■ **Investigator**

Dahyeon Kim / Chief Researcher

Education	2018 ~ 2022	Bucheon University, Department of Beauty Care
Career	2022 ~ 2023	OATC Skin Clinical Test Center, Researcher
	2023 ~ present	Human Skin Clinical Trial Center, Clinical Trial Team, Researcher

Yesol Lee / Researcher

Education	2015 ~ 2017	Jaeneung University, Department of Cosmetics Science
Career	2024 ~ present	Human Skin Clinical Trial Center, Clinical Trial Team, Researcher

HyeonJi Lee / Researcher

Education	2020 ~ 2024	Daejeon University, Department of Beauty Design
Career	2024 ~ present	Human Ethic Skin Clinical Trial Center, Clinical Trial Team, Researcher

List of publications

■ **Principal investigator**

No.	Journal
1	Bohee Yang, Wongyu Hong, Sunghyup Han, Jiwon Byeon, Heejin Song, Seunggyun In, Kwangsung Choi, Jeonghyun Shin. Skin Granulomas associated with Common Variable Immunodeficiency. Journal of Korean Society of Dermatology. 2011:49(7):601-605
2	Heejin Song, Sunghyup Han, Jiwon Byeon, Wongyu Hong, Hyunsook Lee, Jeonghyun Shin, Kwangsung Choi. Sodium Tetradecyl Sulfate 3 Cases of Mucosal Cyst treated with Sclerotherapy. Journal of Korean Society of Dermatology. 2008:46(9):1249-1252
3	Sunghyup Han, Heejin Song, Wongyu Hong, Hyunsook Lee, Jeonghyun Shin, Kwangsung Choi. A Case of Sister Mary Joseph node. Journal of Korean Society of Dermatology. 2008:46(8):1103-1107
4	Heejin Song, Wongyu Hong, Hyunsook Lee, Jeonghyun Shin, Sunyoung Moon, Kwangsung Choi. A Case of Pregnant Woman Tsutsugamushi Disease treated with Azithromycin. Journal of Korean Society of Dermatology. 2008:46(6):859-861
5	Wongyu Hong, Jeonghyun Shin, Kwangsung Choi. Effect of Topical Treatment with Anthralin in Patients with Refractory Alopecia Areata having a Wide Range of Hair Loss. Journal of Korean Society of Dermatology. 2008:46(5):641-647
6	Heejin Song, Sunghyup Han, Wongyu Hong, Hyunsook Lee, Kwangsung Choi, Jeonghyun Shin. A Case of Rheumatic Neutrophil Dermatitis. Journal of Korean Society of Dermatology. 2008:46(4):514-516
7	Wongyu Hong, Jeonghyun Shin, Kwangsung Choi. Clinical Treatment Effect of Germinated Brown Rice Phellinus linteus in Atopic Dermatitis. Korea Journal of Herbology. 2008:23(1):103~108
8	Heejin Song, Wongyu Hong, Hyunsook Lee, Kwangsung Choi, Jeonghyun Shin. A Case ofMacular Amyloidosis Presented as Depressed Patches on the Face. Journal of Korean Society of Dermatology. 2008:46(2):285-288
9	Hyunsook Lee, Sunghyup Han, Heejin Song, Wongyu Hong, Jeonghyun Shin, Kwangsung Choi. A Case of Lichenoid Drug Eruption by Allopurinol. Journal of Korean Society of Dermatology. 2008:46(1);130-133

10	Wongyu Hong, Heejin Song, Hyunsook Lee, Jongrok Lee, Jeonghyun Shin, Kwangsung Choi. A Case of Cowen Syndrome. Journal of Korean Society of Dermatology. 2007:45(8);829-831
11	Hyeyoung Lee, Wongyu Hong, Jeonghyun Shin, Juyoung Noh, Jongrok Lee. A Case of Umbilical Omphalomesenteric Duct Polyp. Journal of Korean Society of Dermatology. 2006:44(11);1342-1344
12	Hyunsook Lee, Wongyu Hong, Jongrok Lee, Jeonghyun Shin, Kwangsung Choi, Yuchan Kim. A Case of Acrosyringeal Nevus. Journal of Korean Society of Dermatology. 2006:44(6);751-753
13	Wongyu Hong, Hyunsook Lee, Jongrok Lee, Kwangsung Choi, Jeonghyun Shin, Yuchan Kim. 2 Cases of Pilomatricoma with Bullous Appearance. Journal of Korean Society of Dermatology. 2006:44(3);330-333
14	Hyunsook Lee, Wongyu Hong, Seunggyun In, Jongrok Lee, Jeonghyun Shin, Kwangsung Choi. A Case of Dermatomyositis Associated with Scarring Alopecic Patches. Journal of Korean Society of Dermatology. 2006:44(2);250-252
15	Wongyu Hong, Jeonghyun Shin, Kwangsung Choi. Effect of Anthralinn Immunotherapy in Patients with Alopecia Areata having a Wide Range of Hair Loss. Journal of Korean Society of Dermatology. 2009:42(9);1130-1137
16	Heejin Song, Wongyu Hong, Sunghyup Han, Jiwon Byeon, Hyunsook Lee, Kwangsung Choi, Jeonghyun Shin. Acral Angioosteoma Cutis. American Journal of Dermatopathology. 2010:32(5):477-478
17	Heejin Song, Sunghyup Han, Wongyu Hong, Hyunsook Lee, Jeonghyun Shin, Kwangsung Choi. Paraneoplastic bullous pemphigoid: Clinical disease activity correlated with enzyme-linked immunosorbent assay index for the NC16A domain of BP180. Journal of Dermatology. 2009:36:66-68
18	Jiwon Byeon, Sunghyup Han, Heejin Song, Wongyu Hong, Hyunsook Lee, Jeonghyun Shin, Kwangsung Choi. A case of supraumbilical skin rash after chemoembolization for hepatocellular carcinoma. Journal of the European Academy of Dermatology and Venereology. 2009:23(12):1458-1459
19	Wongyu Hong, Heejin Song, Hyunsook Lee, Jeonghyun Shin, Kwangsung Choi. Hobnail haemangioma associated with a secondary sexual characteristic. Journal of the European Academy of Dermatology and Venereology. 2009:23:465-466
20	Heejin Song, Wongyu Hong, Hyunsook Lee, Kwangsung Choi, Jeonghyun Shin. Herpes zoster complicated by delayed intracranial haemorrhage. Clinical and Experimental Dermatology. 2009:34:518-540

21	Sunghyup Han, Heejin Song, Wongyu Hong, Hyunsook Lee, Kwangsung Choi,Jeonghyun Shin. Rhabdomyomatous mesenchymal hamartoma of the vagina. Pediatric Dermatology. 2009:26(6):753-755
22	Sunghyup Han, Heejin Song, Wongyu Hong, Hyunsook Lee, Kwangsung Choi, Jeonghyun Shin. A case of adult blaschkitis with features of interface dermatitis. British Journal of Dermatology. 2008:159:231–266
23	Heejin Song, Wongyu Hong, Hyunsook Lee, Jeonghyun Shin, Kwangsung Choi. Intramuscular lipoma of the sternocleidomastoid muscle. J Eur Acad Dermatol Venereol. 2008:22:363–404
24	Hyunsook Lee, Heejin Song, Wongyu Hong, Jeonghyun Shin, Kwangsung Choi. Pseudoxanthoma elasticum-like papillary dermal elastolysis with solar elastosis. J Eur Acad Dermatol Venereol. 2008:22:363–404
25	Shingu Park, Uicheol Lee, Wongyu Hong, Heejin Song, Jeonghyun Shin. A Case of Occupational Allergic Contact Dermatitis due to PVC Hose. Journal of Occupational Health. 2008:50:197-200
26	Jeonghyun Shin, Wongyu Hong, Heejin Song, Kwangsung Choi, Yuchan Kim. Atypical Acute Graft-Versus-Host Disease. American journal of dermatopathology. 2007:29;576-577
27	Byun JW, Hong WK, Han SH, Song HJ, Lee HS, Choi GS, Shin JH. Red scrotum syndrome: successful treatment with oral doxycycline. International Journal of Dermatology. 2012;51(3):362-363

■ **Quality Assurance**

No.	Journal
1	Sentinel Lymph Node Biopsy and Staging of Melanoma Using Lymphoscintigraphy and Gamma-probe
2	Preference of Near-erythemogenic Narrow-band UVB Phototherapy in Psoriasis and Change of Dendritic Cells and Chemokines
3	Effectiveness of Amniotic Membrane Patch in the Treatment of Chronic Ulcers
4	Effects of Keratinocyte Growth Factor (KGF), Epidermal Growth Factor (EGF), and Extracellular Calcium on the Growth of Cultured Psoriatic Keratinocytes
5	Photodynamic Therapy of Actinic Keratoses Using 585nm Dye Laser and Variable Lights
6	A Clinical Analysis of the Risk Factors of Varicose Veins in Korean
7	A Case of Churg-Strauss Syndrome Associated with Small Bowel Perforationfollowing High Dose Systemic Steroid Intravenous Injection
8	A Case of Muticentric Reticulohistiocytosis Misdiagnosed As Rheumatoid Arthritis
9	A Case of Pigmented Clear Cell Acanthoma
10	A Case of SAPHO Syndrome in a Palmoplantar Pustulosis Patient
11	A Case of Xanthoma Disseminatum with Diabetes Insipidus
12	A Case of Chilblain Lupus Erythematosus Associated with Antibodies to SSA/Ro
13	A Case of Primary Mucinous Carcinoma of the Skin
14	A Case of ALK-negative Systemic Anaplastic Large Cell Lymphoma
15	CD4-/CD56+/CD123+ Hematodermic neoplasm showing early liver metastasis

This report has not to be used for any purposes other than those permitted under “the Copyright Act” and “the Trade Secrets Act”. Without the written consent of Human Co., Ltd. Skin Clinical Trial Center, neither the whole report nor any part of it may be transferred, accessed, cited, reproduced, transmitted, or disclosed.